Published in:
01-12-2021 | Esophagus Resection | ASO Author Reflections
ASO Author Reflections: Response to Neoadjuvant Chemotherapy Strengthens the Prognostic Impact of Pathological Stage for Esophageal Squamous Cell Carcinoma
Authors:
Satoru Matsuda, MD, PhD, Hirofumi Kawakubo, MD, PhD, Akihiko Okamura, MD, PhD, Keita Takahashi, MD, PhD, Tasuku Toihata, MD, Ryo Takemura, PhD, Shuhei Mayanagi, MD, PhD, Hiroya Takeuchi, MD, PhD, FACS, Masayuki Watanabe, MD, PhD, FACS, Yuko Kitagawa, MD, PhD, FACS
Published in:
Annals of Surgical Oncology
|
Issue 13/2021
Login to get access
Excerpt
Thorough risk stratification to select candidates appropriate for adjuvant therapy is required for patients with esophageal cancer, based on adjuvant therapy advancement including immunotherapy. Independent of the standardized TNM staging system, the response to neoadjuvant treatment has been shown to predict postoperative survival.
1,
2 To date, to the best of the authors’ knowledge, there are no multicenter investigations that efficiently compare TNM staging and histological response to neoadjuvant therapy. …